The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial ; day:17 ; month:1 ; year:2019 ; pages:1-13
Cancer immunology immunotherapy ; (17.1.2019), 1-13
- Urheber
-
Huijts, Charlotte M.
Lougheed, Sinéad M.
Bodalal, Zuhir
van Herpen, Carla M.
Hamberg, Paul
Tascilar, Metin
Haanen, John B.
Verheul, Henk M.
de Gruijl, Tanja D.
van der Vliet, Hans J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-018-2288-8
- URN
-
urn:nbn:de:101:1-2019021818500200185744
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Huijts, Charlotte M.
- Lougheed, Sinéad M.
- Bodalal, Zuhir
- van Herpen, Carla M.
- Hamberg, Paul
- Tascilar, Metin
- Haanen, John B.
- Verheul, Henk M.
- de Gruijl, Tanja D.
- van der Vliet, Hans J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus
Cancer stem cell subsets and their relationships
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Single-cell gene profiling analysis of human regulatory T cell subsets
Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation
DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus
Cancer stem cell subsets and their relationships
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Single-cell gene profiling analysis of human regulatory T cell subsets
Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation
DOCK8 gene mutation alters cell subsets, BCR signaling, and cell metabolism in B cells
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma
Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus
Cancer stem cell subsets and their relationships
mTOR inhibitor everolimus reduces invasiveness of melanoma cells
mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
Single-cell gene profiling analysis of human regulatory T cell subsets
Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
Immunomodulation of antigen-specific CD8+ T-cells by everolimus and mesenchymal stem cells
Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation